Been watching the pharma sector pretty closely lately, and there's something interesting happening with these large drug stocks that's worth paying attention to. The industry's had a solid run, especially with all the M&A activity and successful pipeline launches we've seen over the past couple years.

The real story here is obesity drugs. Eli Lilly completely dominated the conversation with Mounjaro and Zepbound - both built on tirzepatide, this dual GIP/GLP-1 receptor agonist that's become a massive deal. The company's market cap ballooned past $840 billion largely because of these two products. What's wild is they're not even the only thing driving growth anymore. New approvals like Kisunla, Omvoh, and Jaypirca are starting to contribute meaningfully to their top line. Lilly's currently ranked as a Strong Buy by Zacks, and consensus estimates for their 2024 EPS have been climbing steadily.

Looking at the broader landscape, the big pharma companies sitting on cash piles have been aggressively buying up smaller biotech firms to bolster their pipelines. Makes sense - it's faster than developing drugs from scratch. You saw Morphic get acquired by Eli Lilly, Alpine Immune Sciences picked up by Vertex, and Catalent targeted by Novo Nordisk. These kinds of moves are reshaping the sector.

AstraZeneca's another one worth watching. They've got 12 blockbuster drugs already generating over $1 billion each in sales - Tagrisso, Fasenra, Imfinzi, Lynparza and others are solid performers. The company's been strategic about acquisitions too, grabbing companies like Gracell and Fusion Pharmaceuticals to strengthen their oncology and rare disease portfolios. They're projecting $80 billion in revenues by 2030 with 20 new medicines potentially launching. That's ambitious, but their track record suggests they might pull it off.

Pfizer's interesting because they're turning a corner. COVID money is drying up, sure, but their core business is recovering. Prevnar, Vyndaqel, and Eliquis are holding strong, and they've got new launches like Abrysvo and products from the Seagen acquisition adding momentum. The cash from their pandemic windfall is being deployed smartly - acquisitions, buybacks, debt reduction.

Bayer and Sanofi round out the group I'm tracking. Bayer's got Nubeqa and Kerendia as key drivers, with expansion plans that could unlock more value. Sanofi's immunology drug Dupixent is annualizing around €11 billion in sales and expected to hit €13 billion this year. Their vaccine business alone generates over €5 billion annually.

Now, the headwinds are real. Pipeline setbacks happen, generic competition is always lurking, and there's uncertainty around Medicare price negotiations and FTC scrutiny of deals. Macroeconomic noise and geopolitical tensions add noise too. But here's the thing - the sector's still attracting serious capital despite these challenges, which tells you something about investor conviction.

Valuation-wise, the industry's trading at 18.82X forward P/E versus the S&P 500 at 21.71X, so there's some relative value here. The sector's outperformed the broader medical sector but lagged the market slightly year-to-date, which could mean opportunity depending on your time horizon.

If you're looking at drug stocks and considering where the industry's headed, innovation is the real differentiator. Companies investing heavily in obesity, Alzheimer's, and inflammation treatments are positioning themselves for the next wave. The M&A activity, strong cash flows, and successful pipeline progress across these names suggest there's still runway here. Worth keeping on your radar if you're thinking about healthcare exposure.